KR101333715B1 - Pharmaceutical composition for prevention and treatment of inflammatory diseases comprising extract or fractions of Mastixia arborea C.B.Clarke as an active ingredient - Google Patents

Abstract

The present invention relates to a composition for the prevention and treatment of inflammatory diseases containing Mastixia arborea CBClarke extract or fractions thereof, more specifically, the age at which the mastia alboria extract rapidly increases due to inflammation. suppressing the formation of trick-oxide (nitric oxide) and prostaglandin E ₂ (prostaglandin E ₂₎ and, IL-6 and IL-1beta, and inhibit the production of cytokine, inhibits the expression of iNOS protein in a concentration-dependent manner, inflammatory signaling Phosphorylation of the substance was inhibited, and carrageenan-induced mouse foot edema was also found to have an inhibitory effect. In particular, the ethyl acetate fraction of this plant was also found to have an inhibitory effect on NO production and foot edema. Therefore, the masticia alboria extract or fractions thereof having an excellent anti-inflammatory effect can be usefully used as an active ingredient in the composition for preventing, treating or improving inflammatory diseases, external skin preparations, cosmetic compositions and health foods.

Description

Pharmaceutical composition for preventing and treating inflammatory diseases comprising extract or fractions of Mastixia arborea C.B.Clarke as an active ingredient}

The present invention relates to a pharmaceutical composition for preventing and treating inflammatory diseases using an extract of Mastixia arborea CBClarke or a fraction thereof.

Inflammation refers to the pathological condition of an abscess formed by the invasion of external infectious agents (bacteria, fungi, viruses, various types of allergens). Specifically, when the external bacteria invade specific tissues and proliferate, the white blood cells of the living body recognize the same and actively attack the multiplying external bacteria. The dead cells of the white blood cells generated during this process accumulate in the tissues invaded by the bacteria. At the same time, cell destruction of invading bacteria killed by leukocytes is fused into the invaded tissue to form an abscess. Inflammation of the abscess can be promoted through anti-inflammatory action, which is used to inhibit the growth of invading bacteria using antibacterial agents or to activate macrophage (macrophage) that feeds on foreign substances accumulated in the abscess to digest the foreign substances. And promotes inflammation, such as promoting the function of the macrophages to excrete.

In general, an inflammatory response is a defense process of a living body that attempts to repair and repair the damaged area when an invasion that causes some organic changes in a living cell or tissue is applied. Therefore, the series of reactions include local blood vessels, various tissue cells of body fluids, immune-involved cells, and the like. Recently, with the development of molecular biology, inflammatory diseases have been tried at the molecular level of cytokines, and factors affecting these diseases have been identified one by one.

Inflammatory cytokines and mediators are regulated by elements of the nucleus. For example, NF-κB (nuclear factor-kappa B) is a nuclear protein of the Rel gene family (Rel gene family) and seven types, and in the cytoplasm, combined with the inhibitory kappa B (IκB) exists in an inactive form, but harmful oxygen (kinase) such as reactive oxygen, chemokines such as TNF-α (tumor necrosis factor-alpha) and lipopolysaccharide (LPS), activates IκB kinase and then phosphorylate the IκB Will go out. NF-κB, composed of p50 and p65 heterodimers, is known to promote the expression of genes (tumor necrosis factor or cyclooxide synthase) that, after being activated, migrate to the nucleus and induce an inflammatory response (Oh GT et. al ., Artherosclerosis , 159 (1): 17-26, 2001; Epstein FH et al . , The New England Journal of Medicine , 336 (15): 1066-1071, 1997; Zhang WJ et al ., FASEB J , 15 (130): 2423-2431, 2001; Denk a et al . , J. Biol . Chem . , 276 (30): 28451-28458, 2001; Sahnoun Z et al . , Phsiology , 53 (4): 315-339, 1998; Lindner V Pathobiology , 66 (6): 311-320, 1998; Landry db meat al ., Am . J. Pathol ., 151 (4): 1085-1095,1997; ; Gerritsen ME et al . , Am . J. Pathol ., 147 (2): p278-292, 1995).

Nitric oxide (NO) is produced by the oxidation of L-arginine by Nitric oxide synthase (NOS), which acts as a mediator of inflammation, (Kou and Schroder, Annuals of Surgery 221, 220-235, 1995). Among nitric oxide synthase, inducible nitric oxide synthase (iNOS) is known to be closely related to the overproduction of nitric oxide in cells. Prostaglandin E ₂ (PGE ₂ ) and Leukotriene In addition, PGE ₂ is produced by the cyclooxygenase-2 enzyme (COX-2) as an inflammatory mediator produced from arachidonic acid It is mainly produced in macrophages and monocytes, and macrophages are rapidly induced by inflammatory agents such as riboplysaccharide.

Materials used in animal models for inflammation induction include adjuvant, collagen II, carrageenan, etc. Chondrus In addition to suppression of immune response, carrageenan extracted from cripus is known to have various biological actions such as acute inflammation and induction of chronic inflammation, DIC induction, tumor growth promotion, activation of Hageman factor and kinin, and complement inactivation (Chan WY et al ., J. Pharmacol . Exptl . Therap . , 147: 48,1965).

The most powerful anti-inflammatory drug ever developed by humans is a steroid. However, long-term use is accompanied by side effects. Therefore, in the treatment of inflammation, steroids exert a surprising effect on the first use and completely disappear the symptoms, but this is only for a while, and the symptoms reappear with stopping use of the steroid and the symptoms become worse after repeated use. . Side effects of steroids include side effects such as round polyhedronic face, retention of fluid, adrenal suppression, increased susceptibility to infection, and other psychoses, cataracts, glaucoma, peptic ulcer, delayed wound healing, Have.

Therefore, it is necessary to study a substance which can be safely ingested safely without a separate purification process, which has an effect of suppressing inflammation, and which can be easily used for food, as a medicament containing a natural plant extract as an active ingredient. For example, researchers at the University of Hirosaki and the University of Osaka have found that NF-κB, a protein that regulates genes that cause inflammatory reactions in atopic dermatitis, binds to specific genes of immune cells to produce inflammatory substances, κB to inhibit the action of NF-κB by combining artificial DNA with NF-κB by administering artificial DNA similar to the gene to which κB binds. And Notabis, Switzerland, has developed and marketed "Elidel", a Pimecrolimus ingredient, a treatment for atopic dermatitis, which is a kind of inducer of ascorbic acid and selectively inhibits the release of inflammatory cytokines. In addition, Professor Jang Hyun-wook of Yeungnam University College of Medicine has an extract of three hundreds of herb and leather trees, which are effective in treating asthma and allergies, and signed a technology transfer contract with Korea Pharmaceutical Co., Ltd. for 150 million won and 4% of ordinary fee sales. Public information January 22, 2006).

As an allergic disease treatment agent using antibodies against various types of cytokines and chemokines that are characteristic of allergic diseases so far, allergen treatment using thigh extract, allergic dermatitis treatment using natural herb cactus fermentation extract, and anti-inflammatory disease using specific lactic acid bacteria The development of therapeutic agents has been made, but the development of anti-inflammatory drugs using Mastixia arborea CBClarke has not been made until now.

Mastixia arborea CBClarke belongs to the Cornaceae family, although it is known that the bark of this plant contains an ingredient called loganin (Wieffering, JH, 1966, Phytochemistry). The study of the activity of extracts and components of is unknown.

Thus, the present inventors screened for inflammatory activity in plant extracts abroad, the production of NO and prostaglandin E ₂ and IL-6 and IL-1beta cytosine, the mastia alboria extract is rapidly increased by inflammation It was confirmed that the inhibitory effect of the production of the protein, iNOS protein expression-dependently, inhibited the phosphorylation of inflammatory signaling substances, and inhibits carrageenan-induced mouse foot edema. In addition, the ethyl acetate fraction of this plant was also found to have an inhibitory effect on NO production and foot edema. Accordingly, the present invention has been completed by revealing that the masticia alboria extract or a fraction thereof may be used as an active ingredient of a pharmaceutical composition for preventing or treating various inflammatory diseases including allergy.

An object of the present invention is Mastixia arborea To provide a pharmaceutical composition, skin external preparation, cosmetic composition and health food for preventing and treating inflammatory diseases containing CBClarke) extract or a fraction thereof as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating inflammatory diseases containing Mastixia arborea CBClarke extract or a fraction thereof as an active ingredient.

In addition, the present invention provides a skin external preparation for preventing and improving inflammatory diseases containing a mastia alboria extract or a fraction thereof as an active ingredient.

In another aspect, the present invention provides a cosmetic composition for preventing and improving inflammatory diseases containing a mastia alboria extract or a fraction thereof as an active ingredient.

In addition, the present invention provides a health food for preventing and improving inflammatory diseases containing a mastia alboria extract or a fraction thereof as an active ingredient.

Mastixia arborea CBClarke extract or fractions thereof of the present invention has excellent anti-inflammatory activity and little cytotoxicity, and thus, pharmaceuticals, processed foods, functional foods for the prevention and treatment of inflammatory and allergic diseases. It can be usefully used as an active ingredient of a composition such as food, food additives, functional drinks, or beverage additives.

1 is a diagram showing the inhibitory effect of the mastisia alboria extract on LPS-induced expression of nitric oxide synthase (iNOS);
a; Western blasting;
b; Immunofluorescence staining;
Control group; Negative control treated with DMSO only;
LPS; Positive controls induced with 0.5 [mu] g / ml of LPS; And
LPS + MA; Induced by LPS after 20 μg / ml treatment of Masticia alboria extract.

Figure 2 is a diagram showing the inhibitory effect of the mastissia alboria extract on the production of prostaglandin E ₂ (Prostaglandin E ₂ ) (* P <0.005 or less, ** P <0.05 or less compared to the LPS treatment group);
-; Negative control treated with DMSO only;
+; Positive controls induced with 0.5 [mu] g / ml of LPS;
5; Induction with LPS after 5 μg / ml treatment of Masticia alboria extract;
10; Induction with LPS after 10 μg / ml treatment of Masticia alboria extract;
20; LPS induced after treatment with Masticia alboria extract 20 μg / ml; And
30; Induced by LPS after 30 μg / ml treatment of Masticia alboria extract
Figure 3 is a diagram showing the inhibitory effect of the mastissia alboria extract on the production of sightcaine (* P <0.005 or less, ** P <0.05 or less compared to the LPS treatment group);
a; IL-6 (interleukin-6); And
b; IL-1beta (interleukin-1beta).
Figure 4 is a diagram showing the inhibitory effect of the mastia alboria extract on the phosphorylation of LPS-induced signaling material.
Figure 5 is a diagram showing the inhibitory effect of the mastia alboria extract and ethyl acetate fraction on carrageenan-induced mouse foot edema (* P <0.005 or less than carrageenan treated group);
Control group; PBS alone group;
Carrageenan; Group induced by carrageenan after PBS administration;
MA-40; Group induced with carrageenan after 40 mg / kg of mastia alboria extract;
MA-80; Carrageenan-induced group after administration of 80 mg / kg of mastia alboria extract;
MAE-40; Group induced with carrageenan after 40 mg / kg administration of mastia alboria ethyl acetate fraction;
MAE-80; Group induced by carrageenan after administration of 80 mg / kg of mastia alboria ethyl acetate fraction; And
Indomethacin; Carrageenan induced group after indomethacin 5 mg / kg.
FIG. 6 shows Mastixia arborea CBClarke) is an illustration showing the manufacturing process extracts and fractions.
7 shows Mastixia TLC (Thin Layer Chromatography) of arborea CBClarke extracts and fractions;
T: mastisia alboria extract;
H: mastisia alboria n-hexane fraction;
C: mastisia alboria chloroform fraction;
E: fraction of mastisia alboria ethyl acetate;
B: mastisia alboria butanol fraction; And
W: Water fraction of mastisia alboria.
FIG. 8 shows Mastixia This figure shows the CAD (Charge Aerosol Detector) of arborea CBClarke extract and fraction.

Hereinafter, terms used in the present invention will be described.

The term "inflammation" as used herein refers to the pathological condition of an abscess formed by the infiltration of an external infectious agent (bacteria, fungi, viruses, various kinds of allergens).

As used herein, the term "allergy " refers to a phenomenon in which a living body in contact with an exogenous substance exhibits a different reaction to the substance from the normal.

The term "prophylactic," as used herein, refers to any action that inhibits or delays the progression of an inflammatory disease upon administration of a composition of the present invention.

As used herein, the terms " treatment "and" improvement "refer to all actions by which administration of the composition of the invention improves or alleviates the symptoms of an inflammatory disease.

The term "administering" as used herein is meant to provide any desired composition of the invention to an individual by any suitable method.

The term "individual" as used herein refers to all animals, including humans, monkeys, dogs, goats, pigs, or rats, having a disease in which the symptoms of an inflammatory disease can be improved by administering the composition of the present invention.

The term " pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit or risk rate applicable to medical treatment, including the type of disease, severity, activity of the drug, The time of administration, the route and rate of excretion of the drug, the duration of the treatment, factors including drugs used simultaneously and other factors well known in the medical arts.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing and treating inflammatory diseases containing Mastixia arborea CBClarke extract or a fraction thereof as an active ingredient.

The inflammatory diseases include allergic, dermatitis, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis , Osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, peritonitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases Preferred but not limited to this.

The mastisia alboria extract is preferably but not limited to be produced by a method comprising the steps of:

1) extracting by adding an extraction solvent to the mastia alvoria;

2) filtering the extract of step 1); And

3) Concentrating the filtered extract of step 2) under reduced pressure and drying.

In the above method, the mastissia alboria of step 1) can be used without limitation, such as grown or commercially available.

The mastis alboria is available in both leaves, stems or roots.

The extraction solvent is preferably water, alcohol or a mixture thereof. As the alcohol, C ₁ to C ₂ lower alcohol is preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but it is not limited thereto. The extraction solvent is preferably extracted by adding 1 to 10 times the amount of dried mastisia alboria. The extraction temperature is preferably 30 to 100 DEG C, but is not limited thereto. In addition, the extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, but is not limited thereto. In addition, the extraction number is preferably 3 to 5 times, more preferably 3 times, but not limited thereto.

In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. In addition, the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.

The fraction of the mastisia alboria extract of the present invention is preferably produced by a method of extracting the mastisia alboria extract with an organic solvent, but is not limited thereto.

The organic solvent is preferably n-hexane, chloroform, ethyl acetate or butanol, but is not limited thereto. As the fractions, n-hexane, chloroform, ethyl acetate and butanol were added step by step, and then n-hexane fraction, chloroform fraction, ethyl acetate fraction and butanol fraction obtained by obtaining a soluble fraction in each solvent addition step, and the butanol fraction All the water fractions obtained by removing the remaining water layer after concentration are usable, but preferably n-hexane or ethyl acetate fractions.

In one aspect of the present invention, the MTT assay was performed to determine the cytotoxicity of the mastissia alboria extract or fractions thereof, and the mastisia alboria extract showed almost no cytotoxicity at a concentration of 30 μg / ml or less. It was confirmed that no (see Table 1).

In addition, in one aspect of the present invention, in order to confirm the inhibitory effect of the mastissia alboria extract or fractions thereof, the amount of nitric oxide produced by LPS was measured, and compared to the group treated with LPS alone, In the group treated with alboria extract with LPS, it was confirmed that the concentration of nitric oxide produced was significantly reduced (see Table 2).

In addition, in one aspect of the present invention, in order to determine whether the inhibitory effect of iNOS protein expression of the mastia alboria extract, the expression of iNOS in the artificially induced inflammation of LPS-treated macrophages and Western blotting and As a result of fluorescence staining, it was confirmed that iNOS expression was significantly reduced in cells treated with LPS and mastissia alboria extract compared to cells treated with LPS only (see FIGS. 1A and 1B).

In addition, the eseo one aspect of the present invention, maseuti cyano al boria in order to determine the inflammation inhibitory effect of the extract, confirming the prostaglandin E ₂ production-inhibiting effect results, maseuti cyano al boria concentration dependent manner with the prostaglandin E ₂ production of the extract significantly It was confirmed that the decrease (see Fig. 2).

In addition, it was confirmed that the mastia alboria extract inhibits the production of the cytokines IL-6 and IL-1beta in a concentration-dependent manner (see FIG. 3).

As a result of confirming by Western blotting to determine the effect of the mastissia alboria extract of the present invention on the phosphorylation of the signaling material caused by inflammation induction, the total amount of JNK and ERK, the signaling material was the same, but the phosphorylation form It was confirmed that the protein of did not increase in the cells pretreated with the mastisia alboria (see Fig. 4).

As a result of confirming the effects of the mastissia alboria extract and the ethyl acetate fraction on carrageenan-induced mouse foot edema, the mouse foot was treated with carrageenan-induced foot edema when treated with 40 and 80 mg / kg. It was confirmed that the thickness was reduced (see FIG. 5).

Therefore, the masticia alboria extract of the present invention inhibits the production of NO and prostaglandin E ₂ and IL-6 and IL-1beta cytokines, which are rapidly increased by inflammation, and inhibits the expression of iNOS protein in a concentration-dependent manner. Inhibition of phosphorylation of inflammatory signaling substances, it was confirmed that the effect of inhibiting carrageenan-induced mouse foot edema. In addition, the ethyl acetate fraction of this plant was also found to have an inhibitory effect on NO production and foot edema. Thus, the masticia alboria extract or fractions thereof inhibit NO and prostaglandin E ₂ production and IL-6 and IL-1beta cytokine production, significantly inhibit the expression of iNOS protein, and plant-derived cells. Since it is a safe material without toxicity, it can be seen that it can be usefully used as an active ingredient of the pharmaceutical composition for preventing and treating inflammation-related diseases.

The composition containing the mastisia alboria extract of the present invention or a fraction thereof may further contain one or more active ingredients which exhibit the same or similar functions in addition to the above components.

The composition of the present invention may further comprise a pharmaceutically acceptable additive, wherein pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose Starch glycolate, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, calcium stearate, , White sugar, dextrose, sorbitol and talc. The pharmaceutically acceptable additives according to the present invention are preferably included in the composition in an amount of 0.1 to 90 parts by weight, but are not limited thereto.

That is, the composition of the present invention can be administered in various formulations of oral and parenteral administration at the time of actual clinical administration. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, . &Lt; / RTI &gt; Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, Sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used . Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.

The composition of the present invention may be administered orally or parenterally in accordance with the intended method, and may be administered orally, parenterally or intraperitoneally, rectally, subcutaneously, intravenously, intramuscularly, . The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity.

The dosage of the composition of the present invention varies depending on the weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate and severity of the disease of the patient, the daily dosage is mastis alboria 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, based on the amount of extract, may be administered 1 to 6 times per day.

The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of inflammatory diseases.

The present invention also provides a method for treating an inflammatory disease comprising administering to a subject suffering from an inflammatory disease a composition containing a pharmaceutically effective amount of an extract of Mastiscia alboria or a fraction thereof as an active ingredient.

In addition, the present invention provides a method for preventing inflammatory disease comprising administering to a subject a composition comprising a pharmaceutically effective amount of an extract of mastiscia alboria as an active ingredient.

The pharmaceutically effective amount is 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, but is not limited thereto. The dose may vary depending on the weight, age, sex, health condition, diet, administration period, method of administration, rate of elimination, severity of disease, and the like of a particular patient.

The subject is a vertebrate and preferably a mammal, more preferably an experimental animal such as a rat, rabbit, guinea pig, hamster, dog, cat, and most preferably an ape-like animal such as a chimpanzee or gorilla.

The above-mentioned administration method may be oral or parenteral administration. In the case of parenteral administration, intraperitoneal injection, intramuscular injection, subcutaneous injection, intravenous injection, intramuscular injection, intramural injection, intracerebroventricular injection, Can be administered by injection.

The inflammatory diseases include allergic, dermatitis, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis , Osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay salt, peritonitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases Preferred but not limited to.

Mastisia alboria extract of the present invention significantly lowers the production of nitric oxide (NO) and prostaglandin E ₂ which are rapidly increased by inflammation, significantly inhibits the expression of iNOS protein, and cytotoxicity derived from plants Since it is a safe substance without, it can be seen that it can be usefully used for the prevention and treatment of inflammatory diseases.

In addition, the present invention provides a skin external preparation for preventing and treating inflammatory diseases, which contains a masticia alboria extract or a fraction thereof as an active ingredient.

Inflammatory diseases include allergies, edema, dermatitis, atopy, conjunctivitis, periodontitis, rhinitis, otitis, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, ulcerative colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia Selected from the group consisting of psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, hay fever, perianal inflammation, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis and various acute and chronic inflammatory diseases But the present invention is not limited thereto.

The masticia alboria extract or fractions thereof of the present invention significantly lowered nitric oxide production which is dramatically increased by inflammation, and in particular, the extract significantly lowered prostaglandin E ₂ production and significantly reduced the expression of iNOS protein. As it is suppressed and is a safe substance without cytotoxicity derived from plants, it can be seen that it can be usefully used as an active ingredient in skin external preparations for preventing and treating various inflammatory diseases including allergies.

When the mastiscia alboria extract of the present invention or a fraction thereof is used as an external preparation for skin, it is further added to fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents (foaming) agents), fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, It may contain adjuvants commonly used in the field of dermatology, such as lipid vesicles or any other ingredients commonly used in external preparations for skin. In addition, the components can be introduced in amounts commonly used in the dermatology field.

The dosage of the masticia alboria extract or fractions thereof in the external preparation for skin is 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, but is not limited thereto. Dosage may vary depending on the weight, age, sex, health status, duration of administration, clearance, severity of the disease, and the like of the particular patient.

In another aspect, the present invention provides a cosmetic composition for preventing and improving inflammatory diseases containing a mastia alboria extract or a fraction thereof as an active ingredient.

The masticia alboria extract or fractions thereof of the present invention significantly lower NO and prostaglandin E ₂ production, which are dramatically increased by inflammation, significantly inhibit the expression of iNOS protein, and are free of plant-derived cytotoxicity. Since it is a safe substance, it can be seen that it can be usefully used as an active ingredient of the cosmetic composition for preventing and improving inflammatory diseases.

When using the masticia alboria extract or fractions thereof of the present invention as a cosmetic composition, for example, emulsions, suspensions, microemulsions, microcapsules, obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, aqueous phase, It may be provided in the form of microgranular or ionic (liposomal), nonionic vesicle dispersant, cream, skin, lotion, powder, ointment, spray or cone stick. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant.

The cosmetic composition is in addition to the masticia alboria extract or fractions thereof of the present invention, fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, Fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or It may contain adjuvants conventionally used in the cosmetic field, such as any other ingredient conventionally used in cosmetics.

In addition, the present invention provides a health food for preventing and improving inflammatory diseases containing a mastia alboria extract or a fraction thereof as an active ingredient.

The masticia alboria extract or fractions thereof of the present invention significantly lower NO and prostaglandin E ₂ production, which are dramatically increased by inflammation, significantly inhibit the expression of iNOS protein, and are free of plant-derived cytotoxicity. Since it is a safe substance, it can be usefully used as a component of health food for preventing and improving various inflammatory diseases.

Inflammatory diseases include allergies, edema, dermatitis, atopy, conjunctivitis, periodontitis, rhinitis, otitis, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, ulcerative colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia Selected from the group consisting of psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, hay fever, perianal inflammation, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis and various acute and chronic inflammatory diseases But the present invention is not limited thereto.

The health food of the present invention may be used as it is, or may be used in combination with other food or food ingredients, and may be appropriately used according to a conventional method.

There is no particular limitation on the kind of the health food. Examples of foods to which the above-mentioned mastisia alboria extract or its fractions can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, Soups, drinks, tea, drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in detail with reference to the following Examples, Experimental Examples and Production Examples.

However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples, Experimental Examples and Preparation Examples.

< Example  1> Mastissia Alboria ( Mastixia arborea C.B. Clarke ) Preparation of extract

The masticsia alboria methanol extract of the present invention was purchased from the Overseas Plant Extract Bank of the Korea Center for Biomaterials Herbal Research, Korea Research Institute of Bioscience and Biotechnology, and the herbarium of the Korea Research Institute of Bioscience and Biotechnology (KRIB). A sample of evidence (KRIB 0019270) is kept. Looking at the extraction process, after drying the mastia alboria (leaves, sprigs), add 1 ℓ of methanol to the powdered powder sample 67 g and using an ultrasonic extractor (SDN-900H, SD-ULTRASONIC CO., LTD) 30 times (40KHz, 15 minutes extraction-120 minutes stop) was extracted repeatedly at room temperature. After filtration and concentration under reduced pressure, 4.13 g of a mastia alboria methanol extract (hereinafter referred to as a mastia alboria extract) was obtained. Masticia alboria extract was dissolved in DMSO (dimethyl sulfoxide) to a concentration of 20 mg / ml, and then diluted by concentration.

< Example  2> Mastissia Alborian  menstruum Fraction  Produce

Suspended by adding distilled water to 430 mg of the mastissia alboria extract obtained in Example 1, the same amount of n-hexane was added and mixed, and then the n-hexane soluble fraction and the water soluble fraction were separated. Filtration and concentration under reduced pressure gave 93.4 mg of n-hexane fractions. Then, the same amount of chloroform was removed from the n-hexane fraction and the remaining water layer was added to obtain 69.6 mg of chloroform fraction in the same manner. Ethyl acetate was added to the remaining water layer to obtain 84.4 mg of ethyl acetate fraction in the same manner. The same amount of butanol was added to the remaining water layer to obtain 72.6 mg of butanol fraction in the same manner, and the remaining water layer was concentrated to obtain 78.1 mg of water fraction (FIG. 6).

< Example  3> Mastissia Alboria  Extract and Fraction TLC  Research

The mastisia alboria extract and fractions obtained in Example 1 and Example 2 were dissolved in methanol at a concentration of 10 mg / ml and subjected to silica gel thin layer chromatography (TLC Silica gel 60 F ₂₅₄ , Merck) . As a developing solvent, a mixed solvent of n-hexane: acetone at a ratio of 2: 1 was used. Also, silica gel reverse phase chromatography (TLC Silica gel 60 RP-18 F ₂₅₄ S, Merck) was performed and the developing solvent was 90% methanol (FIG. 2).

< Example  4> Mastissia Alborian  Extract and Fraction UPLC  analysis

The mastissia alboria extract and fractions obtained in <Example 1> and <Example 2> were dissolved in methanol at 10 mg / ml and filtered through a 0.2 μm membrane filter. Ultra Performance Liquid Chromatography (UPLC) was used with the Waters Acquity UPLC system, and the column was ACQUITY UPLC ^™ BEHC ₁₈ (10mm 2.1 mm, id, 1.7m, waters, USA) at 35 ° C. Mobile phase A is initially water and formic acid (100: 0.1, v / v) and mobile phase B is acetonitrile and formic acid (100: 0.1, v / v). Is maintained at 5% for 1 minute, then increased to 60% until 7 minutes, mobile phase B is increased to 100% by 7.5 minutes, and then mobile phase B is maintained at 100% for 9 minutes, and mobile phase is maintained to 9.5 minutes. B was lowered to 5% and stabilized to 5% by 11 minutes for use in the analysis. The flow rate of the mobile phase was 0.4 ml / min and the sample injection amount was 3 μl.

CAD (Charge Aerosol Detector) is a detector that measures the charge by attaching a charge to the materials separated from the UPLC (Chroma Aerosol Detector) can check the relative content and degree of separation in the chromatographic form (Fig. 8). .

< Experimental Example  1> Mastissia Alboria  Extract or its In the fraction  Cytotoxicity test for

In order to confirm cell viability in the mastia alboria extract, the present inventors added DMEM (Dulbecco's Modified Eagle Medium, Gibco Co., Ltd.) medium containing 5% Fetal Bovine Serum (macrophage) of Mouse macrophage Raw264.7 cells. Was suspended at a concentration of 1 10 ⁵ / ml and inoculated in a 96 well plate by 100 μl. After 4 hours the masticia alboria extract or fractions thereof were treated at concentrations of 0, 5, 10, 20 and 30 μg / ml, respectively. After incubation for 24 hours, 10 mg of 5 mg / ml MTT solution was added to each well for 4 hours, and then the supernatant was removed, 100 μl of DMSO was added, and the absorbance was measured at 570 nm. , The cell survival rate was calculated according to the following equation with 100% of the negative control group treated with 0.2% DMSO.

Sample concentration (/) Cell survival rate (%) Negative control group 100.004.68 Mastisia alboria extract 5 101.565.16 10 93.360.58 20 97.136.17 30 95.091.34 Mastisia alboria hexane fraction 5 100.334.33 10 115.097.89 20 81.284.61 30 48.141.21 Mastisia alboria chloroform fraction 5 96.225.27 10 100.5910.13 20 50.143.56 30 32.480.93 Mastisia alboria ethyl acetate fraction 5 102.936.55 10 86.136.81 20 94.780.62 30 91.200.44 Mastisia alboria fraction 5 86.778.21 10 94.846.98 20 90.127.30 30 92.071.98 Mastisia alboria water fraction 5 99.7211.28 10 92.1013.83 20 101.346.89 30 115.7110.24

As a result, as shown in Table 1, it was confirmed that the mastissia alboria extract or fractions thereof had little cytotoxicity up to a concentration of 30 µg / ml (Table 1).

< Experimental Example  1> Mastissia Alboria  Extract Nitric oxide  Generation suppression effect

The inventors have found that inflammation of mastia alboria extract In order to investigate the inhibitory effect, the amount of nitric oxide (NO) induced by lipopolysaccharide (LPS, Sigma) in Raw264.7 cells was measured.

Specifically, 5% Fetal Bovine Serum was added to DMEM (Dulbecco's Modified Eagle Medium, Gibco) medium without phenol red, and the cells were added at a concentration of 2.5 10 ⁵ / ml. The suspension was inoculated with 200 μl in 96 well plate (96 well plate). After attaching for 4 hours, the mastissia alboria extract of the present invention was treated at concentrations of 0, 5, 10, 20 and 30 ㎍ / ml, respectively, and incubated for 1 hour, followed by 0.5 ㎍ / mL LPS treatment. Incubated for 24 hours. 100 μl of the supernatant was collected and placed in a new 96-well plate, and the same amount of a grease reagent (Sigma) was added thereto. The mixture was allowed to react at room temperature for 10 minutes and then transferred to a microplate reader (Bio-Rad) The absorbance was measured at a wavelength of 540 nm. A calibration curve was prepared by using sodium nitrite, and the amount of nitric oxide produced in the culture solution was calculated based on this, and the amount of nitric oxide produced in the lipopolysaccharide treated group was 100%. Was calculated.

As a result, it was confirmed that the production of nitric oxide was rapidly increased in cells treated with LPS only. However, after pretreatment of the mastis alboria extract, the production of LPS significantly reduced the concentration of nitric oxide in the concentration-dependent manner. Confirmed. In particular, when the fractions were treated at a concentration of 30 ㎍ / ㎖, ethyl acetate fractions were found to inhibit the production of nitrooxide 93.13 ± 6.09% without showing cytotoxicity (Table 2).

Sample concentration (/) NO Generation inhibition rate (%) Mastisia alboria extract 5 8.71 ± 12.57 10 30.20 ± 7.45 20 87.26 ± 7.26 30 102.47 ± 3.50 Mastisia alboria hexane fraction 5 25.80 ± 17.18 10 76.90 ± 8.30 20 103.35 ± 1.23 30 105.59 ± 2.59 Mastisia alboria chloroform fraction 5 18.29 ± 12.12 10 78.19 ± 6.48 20 99.91 ± 7.65 30 102.11 ± 7.39 Mastisia alboria ethyl acetate fraction 5 22.82 ± 8.30 10 29.84 ± 6.03 20 58.94 ± 1.56 30 93.13 ± 6.09 Mastisia alboria fraction 5 21.36 ± 7.13 10 40.01 ± 4.21 20 64.16 ± 7.78 30 72.36 ± 2.92 Mastisia alboria water fraction 5 9.40 ± 5.77 10 23.42 ± 6.55 20 39.28 ± 5.90 30 58.71 ± 1.88

< Experimental Example  2> Mastissia Alboria  Extract iNOS  Expression inhibitory effect

<2-1> Western Blasting

The inventors performed western blotting to confirm the inhibitory effect of iNOS protein expression of the mastissia alboria extract.

Specifically, in the same manner as in <Experimental Example 1> The medium was removed from the treated cells, washed with PBS, and then homogenized using a protein eluate (CelLyticTM-MT Tissue Lysis Reagent, Sigma, USA) containing a protease inhibitor cocktail (Roche, USA). It was. The extract was centrifuged at 14000 rpm for 20 minutes and the supernatant and insoluble aggregates were separated. The protein concentration of the separated supernatant was measured using a Bio-Rad protein assay kit (Bio-Rad, USA). In addition, the supernatant was mixed with 5 SDS (0.156M Tris-HCl, pH 6.8, 2.5% SDS, 37.5% glycerol, 37.5 mM DTT) 1: 4 and boiled at 100 ° C for 10 minutes. In a boiled sample, 20 μg of protein was loaded on an SDS 4-12% SDS-PAGE gel and subjected to electrophoresis at 125 V for 2 hours, and separated according to molecular weight. The protein was electrophoresed for 1 hour under conditions of 100 mA per gel. Transferred to PVDF membrane. Anti-iNOS antibody (1: 100, Santa Cruz Biotechnology, USA) was bound to the membrane as primary antibody and photosensitized.

As a result, it was confirmed that the expression level of iNOS protein was rapidly increased in cells treated with LPS only, but the concentration of iNOS protein was decreased in concentration-dependently in LPS treated cells after pretreatment of mastis alboria extract. (FIG. 1A).

<2-2> Immunofluorescence Staining  ( Immunofluoresence )

About 2 10 ⁵ pcs / ml The cells were attached to Permanox chambered plastic slides (Nunc, USA), induced inflammation in macrophages as in Experiment <2-1>, and then the supernatant was removed and phosphate buffer (PBS) Washed with. The cells were fixed with ethanol at 4 ° C for 30 minutes, washed and then blocked with 3% bovine serum albumin at room temperature for 30 minutes. After blocking, the primary antibody [anti-iNOS antibody (1: 100)] was reacted at 4 ° C for one day. After washing 3 times with phosphate buffer, the red (Texas red; Santa Cruz Biotechnology, USA)) was incubated with secondary antibody (Santa Cruz Biotechnology, USA) was reacted for 2 hours under dark conditions at room temperature. (ProLong Gold Antifade reagent, Invitrogen, USA) with phosphate buffer and photographed with a confocal microscope (LSM510m Carl Zeiss, Germany).

As a result, as shown in FIG. 1B, the protein expression of iNOS is rapidly increased in the cells treated with lipopolysaccharide, whereas the expression of the protein is significantly decreased in the cells pretreated with the mastis alboria extract. It was confirmed (FIG. 1B).

< Experimental Example  3> Mastissia Alboria  The extract of prostaglandin E ₂  Generation suppression effect

The inventors have seen maseuti cyano boria extract of prostaglandin E ₂ (Prostaglandin E ₂₎ to confirm the production-inhibiting effect, the <Experiment 1> and Raw264.7 treated maseuti cyano al boria extract and LPS in the same manner After the culture supernatant of the cells was obtained, the production inhibitory effect of prostaglandin E ₂ (Prostaglandin E2) was confirmed using a PGE ₂ assay kit (R & D systems, Minneapolis, USA).

As a result, the production of prostaglandin E2 was increased by LPS, and the concentration of prostaglandin E ₂ was decreased in the concentration-dependent group in the LPS and mastis alboria extracts (FIG. 2).

< Experimental Example  4> Mastissia Alboria  Inhibitory effect of extract on cytokine production

In order to confirm the cytokine production inhibitory effect of the mastia alboria extract, the present inventors analyzed the production of LPS-induced IL-6 (interleukin-6) and IL-1beta in an enzyme immunoassay kit (mouse IL-6 ELISA). set; BD OptEIA ^™ , USA or mouse IL-1beta Enzyme Immunometric Assay Kit; Assay designs, USA).

Specifically, after culturing Raw264.7 cells in the same manner as in <Experimental Example 1>, 100 µl of the supernatant was recovered, and the mixture was dispensed into a 96 well plate coated with mouse immunoglobulin, followed by stirring for 2 hours. Then, the cells were washed four times with a washing solution, and then 100 μl of anti-IL-6 antibody or anti-IL-1beta antibody as the primary antibody was dispensed and reacted for 2 hours. After the reaction, the cells were washed and the secondary antibody was dispensed and reacted for 30 minutes. After washing again, the substrate was incubated for 30 minutes, and the degree of color development was measured at 450 nm with a microplate meter.

As a result, it was confirmed that the amount of each IL-6 and IL-1beta cytokine increased by the treatment of LPS decreased concentration-dependently by pre-treatment of the mastia alboria extract (Fig. 3a and 3b).

< Experimental Example  5> Mastissia Alboria  Inhibitory effect of extracts on signal transduction protein phosphorylation

After treatment with Mastcia alboria extract at a concentration of 30 ㎍ / ㎖ in Raw264.7 cells and a concentration of 0.5 ㎍ / ㎖ LPS after 30 minutes, the cells were collected by time to protease inhibitors and phosphorylation Homogenized using protein eluate containing inhibitor enzyme (phosphatase inhibitor, Roche, Germany). The extract was centrifuged at 14000 rpm for 20 minutes and the supernatant and insoluble aggregates were separated. Proteins of the separated supernatant were quantified, and 20 μg of protein per sample was electrophoresed on SDS 10% SDS-PAGE gel and transferred to PVDF membrane. Blocking the protein-free portion of the protein-transferred membrane with skim milk powder, then using the primary antibody as a whole form of anti-ERK, anti-p38 MAPK, anti-JNK (1: 1000, Santa Cruz Biotechnology, USA) After attaching the antibody of the anti-p38 MAPK and anti-JNK (1: 1000, Enzo, Rarmingdale, NY) or anti-ERK (1: 1000, Cell Signaling Technology, USA) Secondary antibodies were bound sequentially.

As a result, when LPS was treated only with macrophages, it was confirmed that phosphorylated signaling proteins increased with treatment time. In the case of pretreatment of the mastia alboria extract and LPS treatment, the total protein levels of JNK, p38 and ERK were not changed, but the protein expression levels of pJNK and pERK, which are phosphorylated proteins, were inhibited (FIG. 4). .

< Experimental Example  6> Carrageenan ( carrageenan ) Induced mice On foot  About Mastissia Alboria  Extract and Ethyl Acetate Fraction  Inhibitory effect

Since the mastia alboria extract had an excellent anti-inflammatory effect on animal cells, the anti-inflammatory effect was confirmed through animal experiments.

Specifically, 4 to 5 BALB / c female mice (Koatech, Korea) weighing 20-25 g were randomly selected and divided into groups. Masticia alboria extract or ethyl acetate fraction was dissolved in phosphate buffer (PBS) by ultrasound and administered at a concentration of 40 or 80 mg / kg, PBS was administered as a negative control, and indomethacin as a positive control. , Sigma, USA) was administered at a concentration of 5 mg / kg. After 30 minutes, 25 μl of carrageenan (1% v / v) solution dissolved in PBS was injected into the left foot of the mouse to induce inflammation. The thickness of the feet was measured with a caliper (Digital caliper, Niigata Seiki, Japan) before injection of carrageenan, and the degree of inflammation was calculated by measuring again 4 hours after the carrageenan injection.

As a result, the negative control group increased the thickness of the foot by carrageenan 0.90 ± 0.12mm, but it was confirmed that the carrageenan-induced increase in the thickness of the mouse foot was suppressed in the group treated with the mastia alboria extract (40 mg / kg; 0.54 ± 0.07 mm, 80 mg / kg; 0.52 ± 0.08 mm) The mastissia alboria ethyl acetate fraction also has an inhibitory effect on the increase in mouse thickness (40 mg / kg; 0.55 ± 0.06 mm, 80 mg / kg; 0.99 ± 0.08 mm) It was confirmed (Fig. 5).

< Manufacturing example  1> Preparation of Pharmaceutical Formulations

<1-1> Sanje  Produce

2 g of masticia alboria extract of the present invention or a fraction thereof

Lactose 1 g

The above components were mixed and packed in airtight bags to prepare powders.

<1-2> Preparation of tablets

Masticia alboria extract or fractions thereof of the present invention 100 mg

Corn starch 100 mg

Lactose 100 mg

Stearic Acid Magnesium 2 mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

&Lt; 1-3 > Preparation of capsules

Masticia alboria extract or fractions thereof of the present invention 100 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

&Lt; 1-4 >

1 g of masticia alboria extract of the present invention or a fraction thereof

Lactose 1.5 g

1 g of glycerin

Xylitol 0.5 g

After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.

<1-5> Preparation of granules

150 mg of masticia alboria extract or fractions thereof of the present invention

Soy extract 50 mg

Glucose 200 mg

Starch 600 mg

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, and then filled into fabrics.

< Manufacturing example  2> Manufacturing of food

<2-1> Production of flour food

0.5 to 5.0 parts by weight of the mastisia alboria extract of the present invention or its fractions were added to wheat flour and the mixture was used to prepare bread, cake, cookies, crackers and noodles.

<2-2> soup  And juicy ( gravies Manufacturing

0.1 to 5.0 parts by weight of the mastisia alboria extract of the present invention or its fractions were added to soups and juices to prepare health-promoting meat products, noodles and juices.

<2-3> Ground Beef  Produce

10 parts by weight of the mastisia alboria extract of the present invention or its fraction was added to ground beef to prepare ground beef for health promotion.

<2-4> Dairy products ( dairy products Manufacturing

5 to 10 parts by weight of a mastisia alboria extract of the present invention or a fraction thereof was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

<2-5> Solar  Produce

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.

Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.

The mastisia alboria extract of the present invention or its fraction was concentrated under reduced pressure in a vacuum concentrator, sprayed and dried with a hot air drier, and the resulting dried product was pulverized to a size of 60 mesh with a pulverizer to obtain a dried powder.

The grains, seeds and the mastiscia alboria extract of the present invention or fractions thereof were prepared by combining the following ratios.

(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

Masticia alboria extract or fractions thereof (3 parts by weight) of the present invention,

(0.5 part by weight),

Rhubarb (0.5 parts by weight).

< Manufacturing example  3> Manufacturing of beverage

<3-1> Health drink  Produce

5 g of the mastisia alboria extract or fraction thereof of the present invention is added to a homogeneous mixture such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5% And sterilized at the moment, and then packaged in small containers such as glass bottles and plastic bottles.

<3-2> Preparation of vegetable juice

Vegetable juice was prepared by adding 5 g of the masticia alboria extract of the present invention or a fraction thereof to 1,000 tomato or carrot juices.

<3-3> Production of fruit juice

A fruit juice was prepared by adding 1 g of the masticia alboria extract of the present invention or a fraction thereof to 1,000 apple or grape juices.

Claims (11)

A pharmaceutical composition for preventing and treating inflammatory diseases, which contains an extract of Mastixia arborea CBClarke or a fraction thereof as an active ingredient.
The pharmaceutical composition for preventing and treating inflammatory diseases of claim 1, wherein the mastissia alboria is extracted using water, a lower alcohol of C ₁ to C ₂ or a mixture thereof as a solvent.
The pharmaceutical composition according to claim 2, wherein the lower alcohol is ethanol or methanol.
The pharmaceutical composition of claim 1, wherein the fraction is a fraction extracted by adding n-hexane, chloroform, ethyl acetate, or butanol to the masticia alboria extract.
The method of claim 1, wherein the inflammatory disease is allergic, dermatitis, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia (fibromyalgia), psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, hay salt, peritonitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases Pharmaceutical composition for preventing and treating inflammatory diseases, characterized in that any one selected.
A skin external preparation for preventing and treating inflammatory diseases, which contains a mastia alboria extract or a fraction thereof as an active ingredient.
The method of claim 6, wherein the inflammatory disease is allergic, dermatitis, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, hay salt, peritonitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases Skin external preparation for preventing and treating inflammatory diseases.
Cosmetic composition for preventing and improving inflammatory diseases containing a mastia alboria extract or a fraction thereof as an active ingredient.
The method of claim 8, wherein the inflammatory disease is allergic, dermatitis, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, hay salt, peritonitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases Cosmetic composition for preventing and improving inflammatory diseases.
Inflammatory disease prevention and improvement health food containing a mastia alboria extract or a fraction thereof as an active ingredient.
The method of claim 10, wherein the inflammatory disease is allergic, dermatitis, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, hay salt, peritonitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, and acute and chronic inflammatory diseases Inflammatory disease to prevent and improve health food.

Images